FDA Approved: RELAFEN DS — Supplemental Application (Carwin Pharmaceutical Associates, LLC)

View source ↗

Summary

The FDA approved a supplemental application for Relafen DS (nabumetone) submitted by Carwin Pharmaceutical Associates, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Rheumatoid Arthritis

Drugs mentioned

• RELAFEN DS (nabumetone)

Snippet

SUPPL AP for RELAFEN DS (NABUMETONE)